AstraZeneca acquires FDA breakthrough therapy label for asthma drug

By Sophie Chapman
The Anglo-Swedish pharmaceutical company, AstraZeneca, has received a breakthrough therapy label for its asthma treatment. The firm was granted the lab...

The Anglo-Swedish pharmaceutical company, AstraZeneca, has received a breakthrough therapy label for its asthma treatment.

The firm was granted the label from the US Food and Drug Administration (FDA) for its tezepelumab drug targeting a form of severe asthma.

The breakthrough therapy label is expected to aid development by reducing times associated with the progress and regulatory reviews.

The FDA will grant the status to medicines that target serious conditions and have demonstrated encouraging results.

SEE ALSO:

The drug, taken in the form of an injection, aims to be used by a wider range of patients than existing medicines on the market.

During tests of tezepelumab in 2017, dependant on the dose the drug reduced the annual rate of severe asthma attacks in patients by 61% and 71%.

“Tezepelumab is exciting because it has the potential to treat a broad population of severe asthma patients, including those ineligible for currently-approved biologic therapies,” stated Sean Bohen, Executive Vice President of Global Medicines Development and Chief Medical Officer at AstraZeneca.

“The Breakthrough Therapy Designation will help us bring tezepelumab to patients as quickly as possible.”

AstraZeneca has now received seven breakthrough therapy designations from the FDA since 2014.

Share

Featured Articles

Johnson & Johnson: Turning supplier spend into local support

Johnson & Johnson’s Global Supplier Diversity & Inclusion team is growing spending with social enterprises around the globe to expand its impact

Seasonal Affective Disorder’s impact on health & solutions

Dr Ravi Gill & Dr. Naomi Newman-Beinart discuss Seasonal Affective Disorder and its treatments, from vitamin D spray to light therapy

CGI teams up with Totalmobile for digital healthcare service

CGI is driving efficiency in healthcare. Hear from Helena Jochberger, at Manufacturing Digital LIVE, a free virtual event on Wednesday 6th December 2023

Deloitte: generative AI can improve access to healthcare

Technology & AI

Wipro & NVIDIA’s revolutionary healthcare uses generative AI

AI & ML

Healthtech platform CoverSelf extends seed round to US$8.2m

Technology & AI